OR WAIT 15 SECS
Westbury, NY - BioIVT announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.
The FNIH Biomarkers Consortium is a public-private biomedical research partnership. It brings together members of industry, academia, nonprofit and patient advocacy organizations, and government agencies and institutes to develop and support research to qualify promising biomarkers for diagnosing disease, predicting therapeutic response or improving clinical practice.
“We’re proud to contribute our research expertise to support the FNIH Biomarkers Consortium programs. Our research services groups will be able to assist in the development of new assays supporting diagnostic, efficacy and safety biomarker research for cancer, metabolic disorders, neuroscience, and inflammation and immunity applications,” said Amanda Woodrooffe, PhD, vice president and general manager, PHASEZERO® Research Services at BioIVT.
“We are excited to welcome BioIVT as the newest member of the FNIH Biomarkers Consortium. BioIVT’s expertise and commitment to scientific discovery will help us accelerate biomedical research to fight diseases across the world,” said Joseph P. Menetski, PhD, associate vice president for research partnerships, the FNIH.